Home / Market News / $MRTX

$MRTX news and market catalysts

The 5 most recent market catalysts affecting $MRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 0 high impact 3 bullish 0 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Monte Rosa Therapeutics (MRTX) announced the presentation of preclinical data for its gout candidate, MRT-8102, at a medical conference. This is a routine update for a biotechnolog…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics (MRTX) reported Q3 2026 financial results, showcasing a robust cash position of $582.6 million, projected to fund operations into 2029. This strong financia…
Oct 28, 2026 Corporate Catalyst Bullish Impact 65
Monte Rosa Therapeutics Announces Milestone Achievement for MRT-6160 Clinical Study
Monte Rosa Therapeutics (MRTX) announced the receipt of a $37.5 million milestone payment from Novartis (NVS) following the initiation of a second Phase 2 clinical study for their …
Sep 30, 2026 Corporate Catalyst Neutral Impact 75
Monte Rosa Therapeutics To Present Phase 1 Data For MRT-8102 In People With Elevated Cardiovascular Risk On October 1
This headline represents a significant corporate catalyst for Monte Rosa Therapeutics (MRTX). The presentation of Phase 1 data for MRT-8102, a drug targeting people with elevated c…
Sep 8, 2026 Corporate Catalyst Bullish Impact 75
Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease
The $50 million milestone payment is a substantial non-dilutive cash infusion for Monte Rosa Therapeutics, significantly strengthening its balance sheet and extending its cash runw…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.